

# Incidence of Inpatient Constipation Among Migraine Patients Treated With Erenumab: A Retrospective Cohort Study in a US Electronic Health Record Database

V Hoffman<sup>1</sup>, KS Gill<sup>2</sup>, CA Szekely<sup>2</sup>, G Reznor<sup>1</sup>, SM Ezzy<sup>1</sup>, AS Park<sup>2</sup>, R Urman<sup>2</sup>, RK Hernandez<sup>2</sup>, M Navetta<sup>2</sup>, S Lopez-Leon<sup>3</sup>, DE Chou<sup>2</sup>, F Xue<sup>2</sup>, FT Wang<sup>1</sup>

<sup>1</sup>Optum, Boston, MA, USA; <sup>2</sup>Amgen Inc., Thousand Oaks, CA, USA; <sup>3</sup>Novartis Pharmaceuticals Corp, East Hanover, NJ, USA

Migraine Trust Virtual Symposium, 3–9 October, 2020

This study was supported by Amgen, Inc and was carried out under a research collaboration/contract between Optum and Amgen, Inc. Erenumab is co-marketed by Amgen and Novartis.



© Amgen 2020

## Background

- Erenumab (erenumab-aooe in the U.S.) is a calcitonin gene-related peptide (CGRP) receptor antagonist that was approved in the United States (US) on May 2018 as a first in class treatment for migraine prevention in adults
- Constipation was identified as an adverse drug reaction based on data from erenumab clinical trials, and constipation with serious complications has been observed among erenumab users in the post-marketing setting
- Patients with migraine have comorbidities or concomitant medications that increase the risk of developing constipation
- This study describes the incidence of inpatient constipation among all new users of erenumab, and among subsets of new users with select baseline characteristics

## Methods

### Data source: Optum Electronic Health Record (EHR) Database

- US based, 88+M patients from 2007-2020


### Cohort eligibility

- Prescription order for erenumab during the accrual period; only the first identified prescription order was considered
- Age  $\geq$  18 years
- At least 1 migraine diagnosis (ICD-10-CM G43.-) or prescription for a triptan/ergotamine in the prior 12 months
- At least 1 outpatient (OP) visit at least 1 year prior to the erenumab prescription to establish the 12-month baseline period
- No use of any monoclonal antibodies targeting the CGRP pathway in the one year prior to the erenumab prescription

### Index date

- Date of cohort entry (earliest date of meeting all cohort eligibility criteria)

**Figure 1. Cohort study design**



### Follow-up period

- Starting the day following the index date through the earliest of: 1) occurrence of the outcome, 2) prescription for other CGRP antagonists (galcanezumab or fremanezumab), or 3) end of the 90-day risk evaluation window

## Methods (continued)

### Outcome: inpatient constipation

- ICD-10-CM K59.0- in an emergency department (ED) or inpatient (IP) visit
- Any constipation event occurring during an inpatient hospital or ED visit was counted, regardless of the primary reason for the visit.
- Only the first (incident) event identified during the follow-up period was counted in the analysis

### Analysis

- The 90-day incidence proportion was calculated as the number of incident events identified during the 90-day outcome risk window after the index date, divided by the number of cohort members at risk at the start of follow-up
- 95% CIs for the incidence proportions were also calculated
- Incidence proportions among all new users of erenumab, and among subsets of new users by select baseline characteristics, are presented

## Results

Table 1. Incidence of inpatient constipation among new users of erenumab, by select patient characteristics

Baseline characteristics		New users of erenumab	Inpatient constipation	
		N (%)	N	90-day incidence proportion (%; 95% CI)
<b>Overall</b>		<b>9,994 (100.0)</b>	<b>55</b>	<b>0.55 (0.42 – 0.72)</b>
<b>Age<sup>†</sup> group (years)</b>	18 – 34	1,793 (17.9)	12	0.67 (0.38 – 1.17)
	35 – 49	4,056 (40.6)	20	0.49 (0.32 – 0.76)
	50 – 64	3,374 (33.8)	15	0.44 (0.27 – 0.73)
	≥ 65	771 (7.7)	8	<b>1.04 (0.53 – 2.03)*</b>
<b>Sex</b>	Female	8,731 (87.4)	51	0.58 (0.44 – 0.77)
	Male	1,263 (12.6)	4	0.32 (0.12 – 0.81)
<b>BMI (kg/m<sup>2</sup>)</b>	< 18.5	172 (1.7)	1	0.58 (0.10 – 3.22)
	18.5 – 24	2,374 (23.8)	13	0.55 (0.32 – 0.93)
	25 – 29	2,303 (23.0)	5	0.22 (0.09 – 0.51)
	≥ 30	3,723 (37.3)	28	0.75 (0.52 – 1.08)
	Unknown	1,422 (14.2)	8	0.56 (0.29 – 1.11)

Abbreviations: BMI: body mass index; kg/m<sup>2</sup>: kilogram / square meter

\*90-day incidence proportions in red font represent those > 1%.

<sup>†</sup> Mean age (standard deviation): 46.6 (12.7) years;

## Results (continued)

Table 2. Incidence of inpatient constipation among new users of erenumab, by select baseline constipation risk factors

Baseline characteristics		New erenumab users	Inpatient constipation	
		N (%)	N	90-day incidence proportion (%; 95% CI)
<b>Prior constipation or complications</b>	Any constipation (OP, IP, ED)	638 (6.4)	20	<b>3.13 (2.04 – 4.79)*</b>
	Inpatient constipation (IP, ED)	181 (1.8)	12	<b>6.63 (3.83 – 11.23)*</b>
	Complications of constipation (IP, ED) <sup>†</sup>	52 (0.5)	6	<b>11.54 (5.40 – 22.97)*</b>
<b>Potential risk factors for constipation</b>	Irritable bowel syndrome	743 (7.4)	12	<b>1.62 (0.93 – 2.80)*</b>
	Diverticular disease	331 (3.3)	5	<b>1.51 (0.65 – 3.49)*</b>
	Hemorrhoids (not due to pregnancy)	433 (4.3)	9	<b>2.08 (1.10 – 3.90)*</b>
	Diabetes	952 (9.5)	12	<b>1.26 (0.72 – 2.19)*</b>
	Autonomic neuropathy	73 (0.7)	3	<b>4.11 (1.41 – 11.40)*</b>
	Multiple sclerosis	161 (1.6)	1	0.62 ( 0.11 – 3.43)
<b>Medications that may cause constipation</b>	Opioids	4,793 (48.0)	46	0.96 (0.72 – 1.28)
	NSAIDs (prescription and OTC)	5,503 (55.1)	44	0.80 (0.60 – 1.07)
	Anticholinergics	5,649 (56.5)	44	0.78 (0.58 – 1.04)

Abbreviations: ED: emergency department; IP: inpatient; NSAIDs: nonsteroidal anti-inflammatory drugs; OP: outpatient; OTC: over the counter medications

90-day incidence proportions in red font represent those > 1%.

<sup>†</sup>Includes intestinal impaction, megacolon, anal/rectal prolapse, fissure, fistula, ulcer, and ileus in outpatient, inpatient, and emergency department (ED) visits.

## Results (continued)

Table 3. Incidence of inpatient constipation among new users of erenumab, by select characteristics related to migraine

Baseline characteristics		New erenumab users	Inpatient constipation	
		N (%)	N	90-day incidence proportion (%; 95% CI)
<b>Comorbidities related to migraine</b>	Asthma	1,467 (14.7)	12	0.82 (0.47 – 1.42)
	Hypertension	2,633 (26.4)	24	0.91 (0.62 – 1.35)
	Anxiety	3,512 (35.1)	33	0.94 (0.67 – 1.32)
	Depression	2,940 (29.4)	30	<b>1.02 (0.72 – 1.45)*</b>
	Non-migraine headache	4,657 (46.6)	43	0.92 (0.69 – 1.24)
	Chronic pain	5,072 (50.8)	48	0.95 (0.71 – 1.25)
	Insomnia	1,875 (18.8)	17	0.91 (0.57 – 1.45)
	Thyroid disorder	1,879 (18.8)	17	0.90 (0.57 – 1.44)
<b>Migraine preventive agents</b>	Botulinum toxin	3,052 (30.5)	22	0.72 (0.48 – 1.09)
	Anti-epileptics <sup>†</sup>	6,042 (60.5)	42	0.70 (0.51 – 0.94)
	Anti-depressants <sup>‡</sup>	5,317 (53.2)	36	0.68 (0.49 – 0.94)
	Anti-hypertensives <sup>§</sup>	3,989 (39.9)	32	0.80 (0.57 – 1.13)

\*90-day incidence proportions in red font represent those > 1%.

<sup>†</sup>Includes carbamazepine, gabapentin, levetiracetam, pregabalin, topiramate, valproate sodium, valproic acid, divalproex sodium, and zonisamide.

<sup>‡</sup>Includes duloxetine, desvenlafaxine, venlafaxine, amitriptyline, desipramine, doxepin, imipramine, nortriptyline, protriptyline, escitalopram, citalopram, and sertraline.

<sup>§</sup>Includes atenolol, bisoprolol, metoprolol, nadolol, nebivolol, pindolol, propranolol, timolol, verapamil, candesartan, clonidine, and lisinopril.

## Conclusions

- The overall 90-day incidence proportion of inpatient constipation among new users of erenumab (0.55%) was similar to the incidence of serious constipation (0.63%) reported in migraine patients in a real-world setting (Chia et al., 2019)
- The incidence proportion was higher in patients  $\geq 65$  years (1.04%), patients with prior constipation or prior complications of constipation (3.13 – 11.54%), and patients with baseline constipation risk factors (1.26 – 4.11%) other than multiple sclerosis
- The majority of patients who experienced inpatient constipation had pre-existing risk factors for constipation (e.g., 46 of 55 patients with events had opioid use during the baseline period).
- Further research on the incidence of inpatient constipation in non-erenumab users with migraine and older age or baseline constipation risk factors may be helpful to contextualize these findings

### Reference:

Chia V, Park A, Goli V, et al. Incidence of constipation in patients treated with commonly used migraine medications. *Cephalalgia*. 2019;39(1\_suppl):376